I don't know how I missed this stock. I'm ticked. This Gene Bio has basically gone from $33 to $64 this year and I'm just now figuring it out. Geeze look a ways back and it was a $15 busted IPo... This is not good. I blame the Netherlands! I mean could you be farther off the world's stage... Could your earnings reports be more boring...
UniQure
uniQure N.V. engages in the discovery, development, and commercialization of gene therapies especially in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B. <-- This is the big hooplah it's a BILLION dollar opportunity... in early trials it looks great... It will cost half a million a dose... but unlike other drugs for hemophilia it will be taken only Once. A One Time Cure... Oh boy... This smells like a huge winner but it is all ready... How much is priced in.. Not enough if it can blast up on a Big down day for stocks...
The company’s expected earnings growth rate for the current quarter is a superb 27.5%. In fact, the stock’s projected earnings growth rate for the current year is 16.3%, more than the broader Medical - Biomedical and Genetics industry’s expected gain of 9.5%.
Oh boy how high could this stock go?
uniQure jumps after Chardan boosts price target to $175 from $100
MAY 16, 2019 | 10:31 EDT
Chardan analyst Gbola Amusa raised his price target for uniQure (QURE) to $175 from $100 to reflect the company's opportunity in Huntington's disease. The stock in morning trading is up 4.5%, or $2.63, to $61.64. uniQure, a Chardan Top Pick for 2019, could be headed towards a $5B-$10B valuation as support emerges for what could be a "best-in-class, breakthrough" Huntington's disease franchise, Amusa tells investors in a research note. In the second half of 2019, uniQure is expected to make AMT-130 the first one-time gene theraphy to enter the clinic for Huntington's, the analyst adds. Following due diligence, Amusa now expects peak AMT-130 sales of $2.7B, 25% risk-adjusted, in 2026. While the market opportunity for Huntington's is potentially larger than that for Duchenne muscular dystrophy,
uniQure does have some analogy to Sarepta Therapeutics (SRPT), which moved up 114% in 2018, Amusa writes. He keeps a Buy rating on uniQure shares.
Oh man... they drag me back in these bios... my weakness... First off who is Chardan? I've never heard of that outfit... fine... This is a 2nd drug candidate! Now we are talking Huntington's disease. Yikes. Analyst Gbola Amusa... that is such a unique name... I don't know any Gbola's.... For some reason i just say that guy is smart! Indian perhaps, African? A smart dude. Obviously, if he works for Chardan.
Ok I might get a major house PT here before jumping. Why is everything better in the Netherlands!!!!!!